NASDAQ$PROK
ProKidney Corp · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported third quarter financial results
ProKidney reported having nearly $400 million in cash, cash equivalents and marketable securities as of September 30, 2023, and expects cash to fund operations into the fourth quarter of 2025. Research and development expenses were $32.2 million and general and administrative expenses were $14.4 million for the three months ended September 30, 2023. Net loss before noncontrolling interest was $42.0 million for the three months ended September 30, 2023.
- Cash, cash equivalents and marketable securities totaled $396.3 million as of September 30, 2023.
- Cash is expected to fund operations into the fourth quarter of 2025.
- Research and development expenses were $32.2 million for the three months ended September 30, 2023.
- Net loss before noncontrolling interest was $42.0 million for the three months ended September 30, 2023.
Headline financials
Revenue & EPS history
ProKidney · Revenue · Quarterly
$0
Forward guidance
ProKidney expects that existing cash, cash equivalents and marketable securities held at September 30, 2023, will enable funding of operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Tailwinds
- Existing cash, cash equivalents and marketable securities will fund operating expenses and capital expenditure requirements into the fourth quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q3 2023
-2.4%
Avg return
Earnings day
-3.0%
Avg return
5 days after
+2.6%
Avg return
30 days after
25%
4 / 16 earnings
Positive
+18.0%
Q1 2024
Best reaction
-13.1%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.3% | -1.2% | -4.7% | |
| Q4 2025 | -4.0% | -8.9% | +2.3% | |
| Q3 2025 | -8.8% | -16.6% | -24.9% | |
| Q2 2025 | -0.9% | +4.7% | +32.2% | |
| Q1 2025 | -6.0% | -9.3% | -1.4% | |
| Q4 2024 | -6.8% | -7.7% | -23.9% | |
| Q3 2024 | -3.7% | -21.2% | -12.6% | |
| Q2 2024 | -0.5% | +9.1% | +11.5% | |
| Q1 2024 | +18.0% | +50.2% | +22.2% | |
| Q4 2023 | -4.1% | +8.9% | +39.7% | |
| Q3 2023 | -13.1% | -24.4% | +20.0% | |
| Q2 2023 | +0.4% | -14.5% | -37.5% | |
| Q1 2023 | +1.2% | +8.1% | +34.0% | |
| Q4 2022 | -9.8% | -12.9% | -24.6% | |
| Q3 2022 | -4.7% | -14.8% | -23.6% | |
| Q2 2022 | +7.3% | +2.7% | +32.6% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro